|
**Overview**: CRD Allergy Panel**Introduction**: The CRD Allergy Panel is a diagnostic tool designed to diagnose allergen components using serum samples. In India, allergic diseases (rhinitis, asthma, food allergy, anaphylaxis) affect ~20-30 percent of the population, with component-resolved diagnostics (CRD) identifying specific IgE to allergen components (e.g., Ara h 2 in peanut, Cor a 9 in hazelnut, Der p 1 in dust mite) for precise risk stratification and immunotherapy guidance. High morbidity from underdiagnosis in rural/low-SES children, limited component testing access, delayed avoidance or desensitization leading to severe reactions or chronic asthma. Per immunology practices aligned with ICMR and Indian Academy of Allergy Asthma and Immunology guidelines, the test employs immunoassay for component-resolved allergen mix over 1-2 days with high specificity, valuable for distinguishing true allergy from sensitization. This diagnostic falls under allergy screening and targets patients with suspected severe or cross-reactive allergies, addressing accurate component detection to guide safe food introduction, venom immunotherapy, or avoidance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating personalized management, and reducing anaphylaxis burden. Its serum-based approach ensures reliable detection in India's diverse environmental settings.**Other Names**: CRD Allergy Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Component-resolved diagnostics advanced; in India, prominence with rising food allergy awareness.**Purpose**: The test screens for 1 parameter (component resolved diagnostic allergen mix) to guide allergy diagnosis, identify specific triggers, inform risk and therapy.**Test Parameters**: 1. Component Resolved Diagnostic Allergen Mix.**Pretest Condition**: No fasting required; patients should report anaphylaxis, food reactions, asthma, or sensitization history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on reaction severity, triggers, cross-reactivity, family atopy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated allergies including anaphylaxis, benefits of component detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive specific components indicate high-risk allergy, necessitating specialist input. Negative may require follow-up if history suggestive.**Specialist Consultation**: Allergists should be consulted for management.**Additional Supporting Tests**: Skin prick, oral challenge for confirmation.**Test Limitations**: Limited to tested components; comprehensive approach required.**References**: Indian Journal of Allergy Asthma Immunology 2024, CRD Studies India 2023. |
